ArticleKidney international reports2022

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG

Mohit Mathur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.